0001193125-26-205044
SEC filingFibroBiologics granted stock options to executives, including CEO Pete O'Heeron, with vesting over four years.
On May 4, 2026, FibroBiologics' Compensation Committee granted stock options to four top executives under the company's 2022 Stock Plan. The grants are intended to incentivize long-term performance and retention. CEO Pete O'Heeron received options for 92,410 shares, while CFO Jason D. Davis, CSO Hamid Khoja, and General Counsel Ruben A. Garcia each received options for 61,607 shares. All options have an exercise price of $1.38 per share, with a four-year graded vesting schedule: 25% vests on the first anniversary, and the remainder vests in 36 equal monthly installments thereafter, subject to continued service. This compensation structure aligns executive interests with shareholder value over a multi-year horizon.